Bioventus Inc. (BVS)
NASDAQ: BVS · IEX Real-Time Price · USD
7.17
+0.10 (1.41%)
At close: Jul 19, 2024, 4:00 PM
7.19
+0.02 (0.28%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Bioventus Revenue
Bioventus had revenue of $522.74M in the twelve months ending March 30, 2024, with 1.72% growth year-over-year. Revenue in the quarter ending March 30, 2024 was $129.46M with 8.73% year-over-year growth. In the year 2023, Bioventus had annual revenue of $512.35M with 0.04% growth.
Revenue (ttm)
$522.74M
Revenue Growth
+1.72%
P/S Ratio
0.88
Revenue / Employee
$538,910
Employees
970
Market Cap
457.64M USD
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 512.35M | 228.00K | 0.04% |
| Dec 31, 2022 | 512.12M | 81.22M | 18.85% |
| Dec 31, 2021 | 430.90M | 109.74M | 34.17% |
| Dec 31, 2020 | 321.16M | -18.98M | -5.58% |
| Dec 31, 2019 | 340.14M | 20.96M | 6.57% |
| Dec 31, 2018 | 319.18M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Enhabit | 1.04B |
| Pacific Biosciences of California | 200.43M |
| Voyager Therapeutics | 119.04M |
| Theravance Biopharma | 61.51M |
| EyePoint Pharmaceuticals | 50.02M |
| MaxCyte | 44.05M |
| Nano-X Imaging | 10.01M |
| Absci | 5.35M |
BVS News
- 2 months ago - Bioventus Reports First Quarter Financial Results - GlobeNewsWire
- 3 months ago - Bioventus to Report First Quarter of Fiscal Year 2024 Financial Results on May 7, 2024 - GlobeNewsWire
- 4 months ago - Bioventus Announces Fourth Quarter and Full Year 2023 Financial Results - GlobeNewsWire
- 4 months ago - Bioventus to Report Fourth Quarter of Fiscal Year 2023 Financial Results on March 12, 2024 - GlobeNewsWire
- 6 months ago - Bioventus Enters into an Amendment with its Credit Agreement Lenders to Enhance Financial and Operational Flexibility - GlobeNewsWire
- 6 months ago - Bioventus Announces Inducement Equity to President and Chief Executive Officer Robert Claypoole - GlobeNewsWire
- 7 months ago - BIOVENTUS ALERT: Bragar Eagel & Squire, P.C. is Investigating Bioventus Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm - Business Wire
- 7 months ago - Bioventus Names Robert Claypoole as President and Chief Executive Officer - GlobeNewsWire